{"id":475,"date":"2019-01-08T16:32:34","date_gmt":"2019-01-08T15:32:34","guid":{"rendered":"https:\/\/triton.u707.jussieu.fr\/hepatherWP_test\/?p=475"},"modified":"2019-03-29T15:12:30","modified_gmt":"2019-03-29T14:12:30","slug":"actu-a","status":"publish","type":"post","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/","title":{"rendered":"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1)"},"content":{"rendered":"<p>Le 25 mai 2016, Marisol Touraine alors ministre des affaires sociales et de la sant\u00e9 annon\u00e7ait le traitement \u00ab&nbsp;universel&nbsp;\u00bb de l\u2019h\u00e9patite chronique C en France avec des antiviraux directs. La Haute Autorit\u00e9 de Sant\u00e9, en charge notamment de l\u2019\u00e9valuation des produits de sant\u00e9, a sollicit\u00e9 une \u00e9valuation de l\u2019efficacit\u00e9 et de la s\u00e9curit\u00e9 des antiviraux directs chez les patients atteints d\u2019h\u00e9patite chronique C avec une fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1). Cette \u00e9valuation sera r\u00e9alis\u00e9e sur la cohorte HEPATHER et concerne plus de 3200 patients F0\/F1 dont 1500 avaient d\u00e9marr\u00e9 un traitement par antiviraux directs au 31 d\u00e9cembre 2017. Un premier rapport interm\u00e9diaire a \u00e9t\u00e9 rendu en Mai 2018, montre une efficacit\u00e9 virologique sup\u00e9rieure \u00e0 96% chez ces patients, et la bonne tol\u00e9rance de ces m\u00e9dicaments. Le rapport final qui \u00e9valuera \u00e9galement l\u2019\u00e9volution de la qualit\u00e9 de vie per\u00e7ue apr\u00e8s traitement et l\u2019impact clinique est attendu en Mai 2020. Lire la suite\u2026.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 25 mai 2016, Marisol Touraine alors ministre des affaires sociales et de la sant\u00e9 annon\u00e7ait le traitement \u00ab&nbsp;universel&nbsp;\u00bb de l\u2019h\u00e9patite chronique C en France avec des antiviraux directs. La Haute Autorit\u00e9 de Sant\u00e9, en charge notamment de l\u2019\u00e9valuation des produits de sant\u00e9, a sollicit\u00e9 une \u00e9valuation de l\u2019efficacit\u00e9 et de la s\u00e9curit\u00e9 des antiviraux [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-475","post","type-post","status-publish","format-standard","hentry","category-actualites"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1) - ANRS CO22 HEPATHER<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1) - ANRS CO22 HEPATHER\" \/>\n<meta property=\"og:description\" content=\"Le 25 mai 2016, Marisol Touraine alors ministre des affaires sociales et de la sant\u00e9 annon\u00e7ait le traitement \u00ab&nbsp;universel&nbsp;\u00bb de l\u2019h\u00e9patite chronique C en France avec des antiviraux directs. La Haute Autorit\u00e9 de Sant\u00e9, en charge notamment de l\u2019\u00e9valuation des produits de sant\u00e9, a sollicit\u00e9 une \u00e9valuation de l\u2019efficacit\u00e9 et de la s\u00e9curit\u00e9 des antiviraux [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\" \/>\n<meta property=\"og:site_name\" content=\"ANRS CO22 HEPATHER\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-08T15:32:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-03-29T14:12:30+00:00\" \/>\n<meta name=\"author\" content=\"admin_ft\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_ft\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\"},\"author\":{\"name\":\"admin_ft\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502\"},\"headline\":\"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1)\",\"datePublished\":\"2019-01-08T15:32:34+00:00\",\"dateModified\":\"2019-03-29T14:12:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\"},\"wordCount\":218,\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\",\"name\":\"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1) - ANRS CO22 HEPATHER\",\"isPartOf\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\"},\"datePublished\":\"2019-01-08T15:32:34+00:00\",\"dateModified\":\"2019-03-29T14:12:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"name\":\"ANRS CO22 HEPATHER\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization\",\"name\":\"IPLESP UMRS 1136\",\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1\",\"width\":464,\"height\":175,\"caption\":\"IPLESP UMRS 1136\"},\"image\":{\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502\",\"name\":\"admin_ft\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g\",\"caption\":\"admin_ft\"},\"url\":\"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_ft\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1) - ANRS CO22 HEPATHER","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/","og_locale":"fr_FR","og_type":"article","og_title":"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1) - ANRS CO22 HEPATHER","og_description":"Le 25 mai 2016, Marisol Touraine alors ministre des affaires sociales et de la sant\u00e9 annon\u00e7ait le traitement \u00ab&nbsp;universel&nbsp;\u00bb de l\u2019h\u00e9patite chronique C en France avec des antiviraux directs. La Haute Autorit\u00e9 de Sant\u00e9, en charge notamment de l\u2019\u00e9valuation des produits de sant\u00e9, a sollicit\u00e9 une \u00e9valuation de l\u2019efficacit\u00e9 et de la s\u00e9curit\u00e9 des antiviraux [&hellip;]","og_url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/","og_site_name":"ANRS CO22 HEPATHER","article_published_time":"2019-01-08T15:32:34+00:00","article_modified_time":"2019-03-29T14:12:30+00:00","author":"admin_ft","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"admin_ft","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/#article","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/"},"author":{"name":"admin_ft","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502"},"headline":"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1)","datePublished":"2019-01-08T15:32:34+00:00","dateModified":"2019-03-29T14:12:30+00:00","mainEntityOfPage":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/"},"wordCount":218,"publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/","name":"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1) - ANRS CO22 HEPATHER","isPartOf":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website"},"datePublished":"2019-01-08T15:32:34+00:00","dateModified":"2019-03-29T14:12:30+00:00","breadcrumb":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/actu-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/"},{"@type":"ListItem","position":2,"name":"HEPATHER, source de donn\u00e9es pour une \u00e9tude command\u00e9e par la Haute Autorit\u00e9 de Sant\u00e9 concernant l\u2019efficacit\u00e9 virologique et la s\u00e9curit\u00e9 des antiviraux \u00e0 action directe dans le traitement de l\u2019h\u00e9patite C chronique chez les patients avec fibrose h\u00e9patique absente \u00e0 mod\u00e9r\u00e9e (F0\/F1)"}]},{"@type":"WebSite","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#website","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","name":"ANRS CO22 HEPATHER","description":"","publisher":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#organization","name":"IPLESP UMRS 1136","url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","contentUrl":"https:\/\/i0.wp.com\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-content\/uploads\/2019\/02\/logoTagline_anrs_white.png?fit=464%2C175&ssl=1","width":464,"height":175,"caption":"IPLESP UMRS 1136"},"image":{"@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/#\/schema\/person\/66fbad7501a64c79dc989c2c4b672502","name":"admin_ft","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32aec5431cbe09c4fa8b01afcd47f8c21f1b273c5fdfeda86a83dc2bb7241767?s=96&d=mm&r=g","caption":"admin_ft"},"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/author\/admin_ft\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":false,"jetpack_shortlink":"https:\/\/wp.me\/paQKc4-7F","jetpack-related-posts":[{"id":3393,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2024-une-annee-de-preparation-et-de-transition-3-publications-par-lequipe-du-sesstim\/","url_meta":{"origin":475,"position":0},"title":"2024 &#8211; une ann\u00e9e de pr\u00e9paration et de transition. 3 publications par l&rsquo;\u00e9quipe du SESSTIM.","author":"admin_fchau","date":"17 mars 2025","format":false,"excerpt":"L'ann\u00e9e 2024 a \u00e9t\u00e9 marqu\u00e9e par la pr\u00e9paration de la suite de la cohorte HEPATHER dont la date de fin \u00e9tait programm\u00e9e au 31 d\u00e9cembre 2024.Hepat-B proposera de prolonger le suivi des patients atteints d'h\u00e9patite B inclus dans Hepather jusqu'en 2029, avec la r\u00e9alisation de nouvelles collections biologiques. Cette cohorte\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3376,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2023-premiers-travaux-issus-du-chainage-individuel-des-donnees-de-la-cohorte-hepather-avec-le-systeme-national-des-donnees-de-sante-5-publications\/","url_meta":{"origin":475,"position":1},"title":"2023 &#8211; Premiers travaux issus du cha\u00eenage individuel des donn\u00e9es de la cohorte Hepather avec le Syst\u00e8me National des Donn\u00e9es de Sant\u00e9. 5 publications","author":"admin_fchau","date":"17 d\u00e9cembre 2024","format":false,"excerpt":"Le cha\u00eenage avec les donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SDNS) autoris\u00e9 par la commission nationale informatique et libert\u00e9 en 2018 a \u00e9t\u00e9 r\u00e9alis\u00e9 pour plus de 80% des participants de la cohorte qui ont donn\u00e9 leur consentement, \u00e0 partir de la reconstruction du num\u00e9ro d'identification au r\u00e9pertoire\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3372,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/2022-15-travaux-publies-a-partir-des-donnees-de-la-cohorte-hepather\/","url_meta":{"origin":475,"position":2},"title":"2022. 15 travaux publi\u00e9s \u00e0 partir des donn\u00e9es de la cohorte HEPATHER !","author":"admin_fchau","date":"17 d\u00e9cembre 2022","format":false,"excerpt":"Ces \u00e9tudes apportent des avanc\u00e9es importantes dans la compr\u00e9hension des h\u00e9patites virales B et C et de leurs complications, notamment en mati\u00e8re de d\u00e9pistage pr\u00e9coce, de facteurs de risque et de strat\u00e9gies pr\u00e9ventives.Plusieurs \u00e9tudes r\u00e9alis\u00e9es par l'\u00e9quipe de sciences sociales du SESSTIM (Inserm, Universit\u00e9 Aix Marseille et IRD) ont port\u00e9\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3290,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/4-travaux-publies-en-2019-dans-le-domaine-de-lhepatite-virale-c\/","url_meta":{"origin":475,"position":3},"title":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C","author":"admin_fchau","date":"3 novembre 2019","format":false,"excerpt":"4 travaux publi\u00e9s en 2019 dans le domaine de l\u2019h\u00e9patite virale C \u00a0 A notre connaissance, l'\u00e9tude de cohorte ANRS CO22 Hepather a \u00e9t\u00e9 la premi\u00e8re \u00e9tude longitudinale prospective \u00e0 explorer les r\u00e9sultats cliniques associ\u00e9s au traitement par anti-viraux directs (AVD) chez les patients atteints d'h\u00e9patite C chronique, en comparant\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3303,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/deja-11-travaux-publies-en-2021\/","url_meta":{"origin":475,"position":4},"title":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0!","author":"admin_fchau","date":"23 novembre 2021","format":false,"excerpt":"D\u00e9j\u00e0 11 travaux publi\u00e9s en 2021\u00a0! H\u00e9patite virale C\u00a0: Au cours des 4 derni\u00e8res ann\u00e9es, plusieurs \u00e9tudes ont port\u00e9 sur l'identification ou la pr\u00e9diction du carcinome h\u00e9patocellulaire chez les patients infect\u00e9s par l'h\u00e9patite C, avant ou apr\u00e8s la gu\u00e9rison virologique. La biobanque de cohorte a, entre autre, \u00e9t\u00e9 utilis\u00e9e pour\u2026","rel":"","context":"Dans &quot;Actualit\u00e9s&quot;","block_context":{"text":"Actualit\u00e9s","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/actualites\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3204,"url":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/une-communication-large-sur-anrs-co22-hepather-lors-du-congres-francais-de-lassociation-francaise-pour-letude-du-foie-afef-en-octobre-2019\/","url_meta":{"origin":475,"position":5},"title":"Une communication large sur ANRS CO22 Hepather lors du congr\u00e8s fran\u00e7ais de l\u2019Association Fran\u00e7aise pour l\u2019Etude du Foie (AFEF) en octobre 2019","author":"C\u00e9line Dorival Mouly","date":"9 septembre 2019","format":false,"excerpt":"Diff\u00e9rentes \u00e9tudes issues des donn\u00e9es de la cohorte HEPATHER seront pr\u00e9sent\u00e9s au congr\u00e8s de l\u2019AFEF qui se d\u00e9roule du 2 au 5 octobre 2019 \u00e0 Marseille. \u00a0 3 travaux seront pr\u00e9sent\u00e9s \u00e0 l\u2019oral \u00a0: Le vendredi 4 octobre \u00e0 15h42 Le devenir clinique des patients VHC avec ant\u00e9c\u00e9dent de d\u00e9compensation\u2026","rel":"","context":"Dans &quot;Non class\u00e9&quot;","block_context":{"text":"Non class\u00e9","link":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/category\/non-classe\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/comments?post=475"}],"version-history":[{"count":1,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/475\/revisions"}],"predecessor-version":[{"id":3090,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/posts\/475\/revisions\/3090"}],"wp:attachment":[{"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/media?parent=475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/categories?post=475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/triton.iplesp.upmc.fr\/hepather_ANRS\/wp-json\/wp\/v2\/tags?post=475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}